SCHEMBL20181600

SCHEMBL20181600

CCc1nn2ccccc2c1C(=O)c1ccc(O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 2/20 0.43
CYP2C9 P11712 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CYP2C19 P33261 2/20 0.43
ALDH1A1 P00352 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
PDE5A O76074 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
TSHR P16473 1/20 0.43
PDE4A P27815 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
BLM P54132 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
PDE3B Q13370 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20181601 0.86 POLB (0.48) CYP2C9MEN1KMT2AALDH1A1NPSR1
SCHEMBL20181603 0.82 SLC22A12 (0.46) MIFCYP2C9MEN1KMT2ACYP2C19
SCHEMBL24592873 0.82 SLC22A12 (0.38) CYP2C9ALDH1A1EYA3SLC22A12MAPT
SCHEMBL5847756 0.81 MIF (0.48) MIFCYP2C9MEN1KMT2ACYP2C19
SCHEMBL2035471 0.81 EGFR (0.48) MIFCYP2C9MEN1KMT2ACYP2C19
SCHEMBL683926 0.80 MIF (0.50) MIFCYP2C9MEN1KMT2ACYP2C19
SCHEMBL38666633 0.78 EGFR (0.48) MIFCYP2C9MEN1KMT2ACYP2C19
SCHEMBL8878630 0.77 EGFR (0.48) MIFCYP2C9MEN1KMT2ACYP2C19
SCHEMBL1780786 0.77 EGFR (0.53) MIFCYP2C9MEN1KMT2ACYP2C19
SCHEMBL7507671 0.76 EGFR (0.45) MIFCYP2C9MEN1KMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50083-E1 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2024-08-20 US disclosed
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-03-07 US disclosed
EP-3543240-B1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
US-10875865-B2 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-12-29 US disclosed
US-10875865-B2 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-12-29 US disclosed
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-08-20 US disclosed
EP-3632904-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2020-04-08 EP disclosed
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 US disclosed
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 US disclosed
EP-3543240-A1 URAT1 INHIBITOR AND USE THEREOF Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2019-09-25 EP disclosed
WO-2018090921-A1 URAT1 INHIBITOR AND USE THEREOF 江苏新元素医药科技有限公司 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion SLC10A6, SLC10A1, SLC28A1 MIF 1254/4885CYP2C9 2251/4885MEN1 3774/4885
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF SLC14A1, SLC10A6, SLC10A1 MIF 1370/4885CYP2C9 3106/4885MEN1 3652/4885
US-10875865-B2 URAT1 inhibitor and use thereof SLC14A1, SLC10A6, SLC10A1 MIF 1370/4885CYP2C9 3106/4885MEN1 3652/4885
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION SLC10A6, SLC10A1, SLC28A1 MIF 1254/4885CYP2C9 2251/4885MEN1 3774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.